Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden

Published:2023-12-13 Issue: Volume: Page:
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Polyzoi Maria,Ekman Mattias,Reithmeier Anja,Jacob Johanna,Karlsson Emma,Bertranou Evelina,Linderholm Barbro,Hettle Robert^ORCID

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-023-00457-4.pdf

Reference78 articles.

1. Socialstyrelsen och Cancerfonden. Cancer i siffror 2018:populärvetenskapliga fakta om cancer. 2018 29/11/2022].

2. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International agency for research on cancer; 2020.

3. Socialstyrelsen. Statistik om cancer: Bilaga—Tabeller—Statistik om nyupptäckta cancerfall 2021. 2021 29/11/2022].

4. National Quality Registry for Breast Cancer (NKBC). Antal bröstcancerfall Bland alla anmälda fall. Diagnosår: 2022. 2022 29/11/2022].

5. American Joint Committee on Cancer (AJCC). AJCC cancer staging manual. 8th ed. Cham: Springer; 2017.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain;PharmacoEconomics - Open;2024-08-19